FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2263505867> ?p ?o ?g. }

• W2263505867 endingPage "11100" @default.
• W2263505867 startingPage "11100" @default.
• W2263505867 abstract "11100 Background: The purpose of this study was to assess the relationship between estrogen receptor (ER) status, amplification of HER-2, and tumor response to PST with docetaxel and trastuzumab in breast cancers positive for HER-2 by immunohistochemistry (IHC). Long-term disease-free survival data are also reported. Methods: Eligible patients were those with T2 or T3 tumors and overexpression of HER-2 via IHC. Docetaxel 100 mg/sq m q. 3 weeks × 4 with growth factor support and weekly trastuzumab × 12 were given before surgery. The Miller-Payne system was used to define pathologic responses (PR) in the excision specimen (0, 1, 2 - no/minimal response; 3 - 4 partial response, pPR; 5 - complete response, pCR). Adjuvant therapy was given at the discretion of the treating oncologist. Results: Of 22 enrolled patients, 19 were assessable. 17 of the 19 subjects had subsequent FISH confirmation of HER-2 status. Six subjects (31%) had a pCR. Of these, 5 had strong amplification of HER-2 and 5 had tumors that were ER-negative. A pPR occurred in an additional 2 subjects (10%). Of the 11 subjects who had no or minimal PR (Miller-Payne 0 - 2), 8 were found to have no amplification for HER-2 and 9 had tumors that were ER-positive. Postoperative (adjuvant) chemotherapy was given to 17 patients. All 12 patients with ER-positive tumors received adjuvant hormonal therapy. Three patients had an asymptomatic decline in left ventricular ejection fraction (LVEF) of 10 - 15% after anthracycline containing chemotherapy, and one had symptomatic non-ischemic cardiomyopathy of unclear etiology 4 years after completion of study therapy and an anthracycline. With a median follow up of 56 months, all 19 participants are alive and disease-free. Conclusion: PST with a 12-week course of trastuzumab and docetaxel is safe and effective, produces a substantial pCR rate, and may result in excellent long-term recurrence-free and overall survival. The subset of patients with tumors that were IHC-positive, but FISH-negative for HER-2, and ER-positive had minimal or no response to therapy, highlighting the importance of identifying patients most likely to respond to trastuzumab-based regimens. [Table: see text]" @default.
• W2263505867 created "2016-06-24" @default.
• W2263505867 creator A5038232707 @default.
• W2263505867 creator A5055934379 @default.
• W2263505867 creator A5060904857 @default.
• W2263505867 creator A5062558351 @default.
• W2263505867 creator A5069042432 @default.
• W2263505867 creator A5081194987 @default.
• W2263505867 date "2007-06-20" @default.
• W2263505867 modified "2023-09-27" @default.
• W2263505867 title "Predictors of response to primary systemic therapy (PST) with docetaxel and trastuzumab in HER2-positive breast cancer" @default.
• W2263505867 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.11100" @default.
• W2263505867 hasPublicationYear "2007" @default.
• W2263505867 type Work @default.
• W2263505867 sameAs 2263505867 @default.
• W2263505867 citedByCount "0" @default.
• W2263505867 crossrefType "journal-article" @default.
• W2263505867 hasAuthorship W2263505867A5038232707 @default.
• W2263505867 hasAuthorship W2263505867A5055934379 @default.
• W2263505867 hasAuthorship W2263505867A5060904857 @default.
• W2263505867 hasAuthorship W2263505867A5062558351 @default.
• W2263505867 hasAuthorship W2263505867A5069042432 @default.
• W2263505867 hasAuthorship W2263505867A5081194987 @default.
• W2263505867 hasConcept C121608353 @default.
• W2263505867 hasConcept C126322002 @default.
• W2263505867 hasConcept C143998085 @default.
• W2263505867 hasConcept C204232928 @default.
• W2263505867 hasConcept C2776694085 @default.
• W2263505867 hasConcept C2776802502 @default.
• W2263505867 hasConcept C2777863537 @default.
• W2263505867 hasConcept C2777910003 @default.
• W2263505867 hasConcept C2777982462 @default.
• W2263505867 hasConcept C2779786085 @default.
• W2263505867 hasConcept C2781190966 @default.
• W2263505867 hasConcept C530470458 @default.
• W2263505867 hasConcept C71924100 @default.
• W2263505867 hasConceptScore W2263505867C121608353 @default.
• W2263505867 hasConceptScore W2263505867C126322002 @default.
• W2263505867 hasConceptScore W2263505867C143998085 @default.
• W2263505867 hasConceptScore W2263505867C204232928 @default.
• W2263505867 hasConceptScore W2263505867C2776694085 @default.
• W2263505867 hasConceptScore W2263505867C2776802502 @default.
• W2263505867 hasConceptScore W2263505867C2777863537 @default.
• W2263505867 hasConceptScore W2263505867C2777910003 @default.
• W2263505867 hasConceptScore W2263505867C2777982462 @default.
• W2263505867 hasConceptScore W2263505867C2779786085 @default.
• W2263505867 hasConceptScore W2263505867C2781190966 @default.
• W2263505867 hasConceptScore W2263505867C530470458 @default.
• W2263505867 hasConceptScore W2263505867C71924100 @default.
• W2263505867 hasIssue "18_suppl" @default.
• W2263505867 hasLocation W22635058671 @default.
• W2263505867 hasOpenAccess W2263505867 @default.
• W2263505867 hasPrimaryLocation W22635058671 @default.
• W2263505867 hasRelatedWork W141138677 @default.
• W2263505867 hasRelatedWork W1966804628 @default.
• W2263505867 hasRelatedWork W1986355551 @default.
• W2263505867 hasRelatedWork W2112721704 @default.
• W2263505867 hasRelatedWork W2171229478 @default.
• W2263505867 hasRelatedWork W2398495979 @default.
• W2263505867 hasRelatedWork W2407758792 @default.
• W2263505867 hasRelatedWork W2415670259 @default.
• W2263505867 hasRelatedWork W2969515167 @default.
• W2263505867 hasRelatedWork W3091016457 @default.
• W2263505867 hasVolume "25" @default.
• W2263505867 isParatext "false" @default.
• W2263505867 isRetracted "false" @default.
• W2263505867 magId "2263505867" @default.
• W2263505867 workType "article" @default.